

Abiraterone

Section

Hormones and antihormones
 Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Aclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to [tiotropium bromide](#) pour

Chronic obstructive pulmonary disease

Adalimumab

Section

Immunomodulators for non-malignant disease
 Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;
 10 mg per 0.2 mL; 20 mg per 0.4 mL

Medicines for juvenile joint diseases

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;
 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Juvenile idiopathic arthritis

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) pour

Other specified malignant neoplasms of
 bronchus or lung

Alteplase

Section

Thrombolytic medicines
 Parenteral > General injections > IV: 10 mg in vial powder for injection; 20
 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Cerebral ischaemic stroke

Amodiaquine + sulfadoxine + pyrimethamine

Section

[Antimalarial medicines](#) > For chemoprevention

Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package

Indications

Malaria

Amoxicillin

Section

[Access group antibiotics](#)

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Indications

Premier choix

Periapical abscess without sinus

Amoxicillin + clavulanic acid

Section

[Access group antibiotics](#)

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

[Antituberculosis medicines](#)

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Second choix

Other specified prophylactic measures

Multi-drug resistant Mycobacterium tuberculosis

Apixaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran pour

Venous thromboembolism

Therapeutic equivalent to dabigatran pour

Other specified atrial fibrillation

Aprepitant

Section

Antiemetic medicines

Oral > Liquid: 125 mg powder for oral suspension (in sachet)

Oral > Solid: 80 mg; 125 mg; 165 mg

Indications

Nausea or vomiting

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Azithromycin

Section

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Premier choix

Typhoid fever

Paratyphoid fever

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Carbetocin

Section

Uterotonics

Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to methimazole pour

Thyrotoxicosis

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Malignant neoplasms of cervix uteri

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

Premier choix

Other specified prophylactic measures

co-prescrire avec metronidazole

Other specified prophylactic measures

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

Premier choix

Typhoid fever

Paratyphoid fever

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choix

Other specified prophylactic measures

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab pour](#)

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab pour](#)

Crohn disease site

Therapeutic equivalent to [adalimumab pour](#)

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab pour](#)

Juvenile idiopathic arthritis

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Indications

Premier choix

Typhoid fever

Paratyphoid fever

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cyclophosphamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Indications

Plasma cell myeloma

Dabigatran

Section

Medicines affecting coagulation

Oral > Solid: 110 mg; 150 mg

Indications

Venous thromboembolism

Other specified atrial fibrillation

Dengue vaccine

Section

Recommendations for some high-risk populations

All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

Dexamethasone

Section

Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Indications

Plasma cell myeloma

Diazoxide

Section

Medicines for hypoglycaemia

Oral > Liquid: 50 mg per mL

Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Plasma cell myeloma

Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran pour

Venous thromboembolism

Therapeutic equivalent to dabigatran pour

Other specified atrial fibrillation

Enzalutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to abiraterone pour

Malignant neoplasms of prostate

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab pour

Axial spondyloarthritis

Therapeutic equivalent to adalimumab pour

Crohn disease site

Therapeutic equivalent to adalimumab pour

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to adalimumab pour

Juvenile idiopathic arthritis

Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid: 600 mg

Indications

African trypanosomiasis

African trypanosomiasis

Fosfomycin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) pour

Other specified malignant neoplasms of bronchus or lung

Gentamicin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

Second choix

Other specified prophylactic measures

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 20 mg granules

Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide pour

Chronic obstructive pulmonary disease

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab pour

Axial spondyloarthritis

Therapeutic equivalent to adalimumab pour

Crohn disease site

Therapeutic equivalent to adalimumab pour

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to adalimumab pour

Juvenile idiopathic arthritis

Imipenem + cilastatin

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to meropenem pour

Multi-drug resistant Mycobacterium tuberculosis

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab pour

Axial spondyloarthritis

Therapeutic equivalent to adalimumab pour

Crohn disease site

Therapeutic equivalent to adalimumab pour

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to adalimumab pour

Juvenile idiopathic arthritis

Ivermectin

Section

Medicines for ectoparasitic infections

Oral > Solid > tablet: 3 mg

Indications

Scabies

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Methicillin resistant Staphylococcus aureus

Vancomycin resistant Staphylococcus aureus

Vancomycin resistant Enterococcus

Lisinopril + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

Essential hypertension

Lisinopril + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

Essential hypertension

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Meropenem

Section

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Methimazole

Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 5 mg; 10 mg; 20 mg

Indications

Thyrotoxicosis

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

Premier choix

co-prescrire avec cefazolin

Other specified prophylactic measures

Multiple micronutrient powder

Section

Vitamins and minerals

Sachets containing:

- iron (elemental) 12.5 mg (as coated ferrous fumarate)

- zinc (elemental) 5 mg

- vitamin A 300 micrograms

- with or without other micronutrients at recommended daily values

Indications

Iron deficiency anaemia

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Melanoma of skin

Oral rehydration salts - zinc sulfate

Section

Medicines used in diarrhoea

Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)

Indications

Diarrhoea

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Malignant neoplasms of cervix uteri

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pembrolizumab

Section

Immunomodulators

Indications

Therapeutic equivalent to nivolumab pour

Melanoma of skin

Phenoxyethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

Premier choix

Periapical abscess without sinus

Plazomicin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Prednisolone

Section

Hormones and antihormones

Oral > Solid: 5 mg; 25 mg

Indications

Plasma cell myeloma

Malignant neoplasms of prostate

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone pour

Plasma cell myeloma

Therapeutic equivalent to prednisolone pour

Malignant neoplasms of prostate

Procarbazine

Section

Cytotoxic medicines

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran pour

Venous thromboembolism

Therapeutic equivalent to dabigatran pour

Other specified atrial fibrillation

Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

Oral > Solid: 500 mg + 25 mg tablet

Oral > Solid: 250 mg + 12.5 mg tablet

Indications

Malaria due to Plasmodium falciparum

Malaria

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to linezolid pour

Methicillin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Enterococcus

Telmisartan + amlodipine

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

Thalidomide

Section

Immunomodulators
Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease
Respiratory > Inhalation > dry powder: 18 µg capsule
Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation

Indications

Chronic obstructive pulmonary disease

Tranexamic acid

Section

Other medicines administered to the mother
Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Postpartum haemorrhage

Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide pour

Chronic obstructive pulmonary disease